CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar's founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar's efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases because of the underlying impact of mitochondrial dysfunction. The company's lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has 4 preclinical programs: CB5138 Analogs for fibrotic diseases, CB5064 Analogs for COVID-19 associated ARDS, MBT5 Analogs for CXCR4-related cancer and orphan diseases, and MBT3 Analogs for cancer immunotherapy.

CWBR stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


12 Aug 21
16 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from CohBar earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1.6M 1.6M 1.6M 1.6M 1.6M 1.6M
Cash burn (monthly) 71.4K 874.51K 1.73M 1.35M 1.44M 1.12M
Cash used (since last report) 253.84K 3.11M 6.16M 4.8M 5.13M 3.99M
Cash remaining 1.35M -1.51M -4.56M -3.2M -3.53M -2.38M
Runway (months of cash) 18.9 -1.7 -2.6 -2.4 -2.4 -2.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
14 Sep 21 Joanne Yun Stock Option Common Stock Grant Acquire A No No 1.18 200,000 236K 200,000
18 Aug 21 Jeffrey Francis Biunno Common Stock Gift Acquire G Yes No 0 4,000 0 5,000
18 Aug 21 Jeffrey Francis Biunno Common Stock Gift Dispose G No No 0 4,000 0 31,152
18 Aug 21 Joseph J. Sarret Common Stock Buy Acquire P No No 1.12 20,000 22.4K 20,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

12.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 39 50 -22.0%
Opened positions 8 4 +100.0%
Closed positions 19 7 +171.4%
Increased positions 8 23 -65.2%
Reduced positions 17 8 +112.5%
13F shares
Current Prev Q Change
Total value 13.34M 14.09M -5.4%
Total shares 4.17M 6.64M -37.2%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Vanguard 2.02M $2.82M +48.6%
Geode Capital Management 359.28K $502K -32.9%
BLK Blackrock 341.23K $478K -76.0%
Optimum Investment Advisors 302.61K $424K +3.4%
Ergoteles 158.6K $222K NEW
DB Deutsche Bank AG - Registered Shares 148.66K $208K -12.8%
Millennium Management 143.31K $201K NEW
Renaissance Technologies 96K $134K -82.4%
HRT Financial 95.32K $133K NEW
NTRS Northern Trust 95.04K $133K -71.8%
Largest transactions
Shares Bought/sold Change
BLK Blackrock 341.23K -1.08M -76.0%
Vanguard 2.02M +659.01K +48.6%
Renaissance Technologies 96K -448.51K -82.4%
WFC Wells Fargo & Co. 3.3K -420.15K -99.2%
STT State Street 0 -411.18K EXIT
NTRS Northern Trust 95.04K -241.7K -71.8%
Squarepoint Ops 0 -189.07K EXIT
Geode Capital Management 359.28K -176.21K -32.9%
Ergoteles 158.6K +158.6K NEW
Millennium Management 143.31K +143.31K NEW

Financial report summary

CognexDurectExelonTerns Pharmaceuticals
Content analysis
H.S. sophomore Good
New words: absolute, ALT, analyze, antiviral, appointment, April, AST, baseline, compound, content, CRO, density, dexamethasone, downstream, ESPP, exploratory, fashion, fraction, golden, hamster, histologic, histological, imaging, infection, Magnetic, Mine, nonqualified, pharmacokinetic, proportion, proton, Qualitative, Quantitative, resonance, Syrian, trend, understand, Unregistered, vaccination, visit
Removed: Aricept, Avandia, belief, called, clinic, composition, daily, donepezil, Exelon, expanded, galantamine, memantine, metformin, million, NAFLD, Namenda, nonalcoholic, oral, pioglitazone, Razadyne, rivastigmine, rosiglitazone, sensitizer, substantially